MALVERN, Pa.--(BUSINESS WIRE)--Orthovita, Inc. (NASDAQ: VITA), a spine and biosurgery company, today announced that Dr. Maarten Persenaire, its Chief Medical Officer, will assume lead responsibility for the CORTOSS clinical program and research and development. As previously announced, the pivotal CORTOSS clinical trial was fully enrolled in February 2007. If data from the pivotal study is supportive, Orthovita intends to seek clearance to market CORTOSS through a 510(k) submission
